BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 18, 2024
See today's BioWorld
Home
» Ambrx Lands Another Pharma In Potential $300M Astellas Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ambrx Lands Another Pharma In Potential $300M Astellas Deal
April 8, 2013
By
Marie Powers
No Comments
Privately held Ambrx Inc. gained another partner for one of its signature technologies, attracting Tokyo-based Astellas Pharma Inc. to an oncology-focused discovery and development collaboration in antibody drug conjugates (ADCs).
BioWorld